ABSTRACT -To elucidate the mechanisms underlying adriamycin resistance, adriamycin resistancerelated genes were explored using the budding yeast Saccharomyces cerevisiae as a useful eukaryotic model. The CLN1 and CLN2 genes, encoding G1 cyclin, and the ERG13 gene, encoding 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase, were identified.
INTRODUCTION
Adriamycin is a representative anthracycline used to treat various cancers, such as malignant lymphoma, breast cancer, and gastrointestinal cancer (Gewirtz, 1999; Benjamin et al., 1974) . However, effective cancer therapy with adriamycin has been hampered by adverse effects and the natural and acquired resistance of cancer cells (Hortobagyi, 1997) . The adverse effects of adriamycin include cardiac toxicity, myelosuppression, and gastrointestinal disorders. In particular, cardiac toxicity is a common, irreversible, and severe adverse effect that is characteristic of anthracyclines (Booser and Hortobagyi, 1994) . The mechanisms underlying these toxic side effects remain unclear.
The mechanisms responsible for the acquired resistance of cancer cells to adriamycin include the overexpression of drug-efflux transporters, such as P-glycoprotein and multidrug resistance proteins (MRP), and qualitative and quantitative alterations in topoisomerase II, a target molecule of adriamycin (Minotti et al., 2004) . However, the resistance of some adriamycin-resistant cells cannot be explained by these mechanisms (Boquete et al., 2001) , suggesting the existence of some unknown resistance mechanisms. We herein explored whether genes conferred adriamycin resistance to yeast when overexpressed using an open reading frame (ORF) library of budding yeast (Saccharomyces cerevisiae), a useful eukaryotic model.
MATERIALS AND METHODS

Screening for adriamycin resistance genes using a yeast ORF library
The S. cerevisiae BY4742 strain (MATα, his3 1, leu2 0, lys2 0, ura3 0) was transformed with a yeast ORF collection (Open Biosystems, Huntsville, AL, USA) by the lithium acetate procedure (Hwang et al., 2009 ). The collection was designed for protein overexpression of over 4,900 S. cerevisiae genes. These genes are controlled by the GAL1 promoter in the URA3-based highcopy plasmid BG1805. Transformants were grown in synthetic dextrose (SD) liquid medium without uracil (-Ura) at 30°C. To induce gene expression, we incubated the Ura + transformants in synthetic galactose (SG) medium containing 2% raffinose (+Raf) without uracil (-Ura) for 6 hr. Subsequently, transformants were cultured (1 × 10 4 cells/200 μl/well) in SG (-Ura) liquid medium containing 80 μM adriamycin in 96-well plates. This concentration of adriamycin inhibits the growth of wild-type BY4742 cells. We isolated transformed cells that rapidly grew and formed aggregates in the presence of adriamycin. In this way, we obtained aggregates that exhibited adriamycin resistance. We isolated plasmids from the cells and amplified them in Escherichia coli (Takahashi et al., 2010) . We reintroduced each plasmid into BY4742 cells to confirm the associated phenotypes. We then selected the plasmid that conferred the strongest resistance to adriamycin for further study. We determined the Overexpression of CLN1, CLN2, or ERG13 increases resistance to adriamycin in Saccharomyces cerevisiae Tsutomu Takahashi, Shingo Nakashima, Takuro Masuda, Shigehiro Yoneda, Gi-Wook Hwang and Akira Naganuma ORF sequence in the selected plasmid with an automated DNA sequencer: a CEQ™ 2000 Genetic Analysis System (Beckman Coulter, Fullerton, CA, USA).
Quantitation of adriamycin sensitivity of yeast cells
We incubated yeast cells in SG medium containing 2% raffinose (+Raf) without uracil (-Ura) for 6 hr. Yeast cells were suspended in liquid SG medium (-Ura) at 1 × 10 4 , 2 × 10 3 , 4 × 10 2 and 8 × 10 cells/ml. Five microliters of each suspension of cells was spotted on agar-solidified SG medium that contained 80 μM adriamycin. Plates were photographed after incubation for 48 hr at 30°C.
RESULTS AND DISCUSSION
To identify genes that confer adriamycin resistance to yeast when overexpressed, an ORF-expression plasmid library was introduced into wild-type yeast, BY4742, to obtained transformants. The transformants were cultured on SG (-Ura) liquid medium containing galactose to induce gene expression. Subsequently, the transformants were cultured on SG (-Ura) liquid medium containing adriamycin at a concentration of 80 μM to prevent the growth of wild-type yeast transformed with empty vector. From this procedure, nine yeast clones were obtained. Plasmids were extracted from the adriamycin-resistant strains and introduced into a parent strain, BY4742. Six yeast strains exhibited resistance to adriamycin. These plasmid-carrying yeast strains were sensitive to adriamycin on SD (-Ura) liquid medium containing glucose. This demonstrates that genes inserted into the plasmids conferred adriamycin resistance to yeast when overexpressed. The ORFs inserted into the plasmids in these adriamycinresistant yeast strains were sequenced to identify CLN1, CLN2, and ERG13 as adriamycin resistance genes (Fig. 1) .
Both CLN1 and CLN2 genes encode G1 cyclin, which is involved in G1 to S phase cell cycle progression. The G1 cyclins of budding yeast include Cln1, Cln2, and Cln3 (Tyers et al., 1993; Oehlen and Cross, 1994) . CLN3 overexpression barely influenced adriamycin sensitivity (data not shown). Cln1, Cln2, and Cln3 may have different functions (Stuart and Wittenberg, 1995; Tyers et al., 1993; Manukyan et al., 2008; Grabinska and Palamarczyk, 2002) . The different functions of the G1 cyclins may influence adriamycin resistance mechanisms. Cyclin E-overexpressing mammalian cells become resistant to adriamycin (Sgambato et al., 2003) but the mechanism responsible for this remains unclear. Multiple G1 cyclins also exist in mammalian cells (Lee and Yang, 2003) . Identifying G1 cyclins involved in adriamycin resistance should elucidate the changes in cell-cycle regulation that lead to adriamycin resistance.
The ERG13 gene encodes 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase in the mevalonate pathway (Parks et al., 1995; Grabinska and Palamarczyk, 2002) . Its relationship with sensitivity to anticancer agents remains unknown. Investigating the relationship between HMG-CoA synthase and adriamycin resistance should yield important findings that may elucidate adriamycin resistance mechanisms. 
